API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.drreddys.com/cms/cms/sites/default/files/2024-07/Press%20Release%20-%20Dr.%20Reddy%27s%20-%20EMA%20CHMP%20positive%20opinion.pdf
https://www.indianpharmapost.com/diagnostic-center/pfizer-reports-positive-results-from-echelon-3-study-15773
https://www.fiercepharma.com/pharma/roche-columvi-earlier-dlbcl-faces-questions-over-inconsistent-patient-survival-data
https://www.globenewswire.com/news-release/2024/06/15/2899263/0/en/Roche-s-Phase-III-STARGLO-study-demonstrates-Columvi-significantly-extends-survival-in-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html
https://www.gene.com/media/press-releases/15021/2024-04-14/genentechs-columvi-meets-primary-endpoin
https://www.globenewswire.com/news-release/2024/04/04/2857466/0/en/PolTREG-identifies-promising-efficacy-biomarker-for-Type-1-diabetes-in-patients-treated-with-its-Treg-therapy-in-combination-with-rituximab.html
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-overall-survival-phase-3-trial
https://www.ema.europa.eu/en/documents/overview/ruxience-epar-medicine-overview_en.pdf
https://www.globenewswire.com//news-release/2023/12/12/2794525/0/en/ADC-Therapeutics-Announces-Initial-Results-from-Investigator-Initiated-Phase-2-Clinical-Trial-Evaluating-ZYNLONTA-in-Combination-with-Rituximab-in-Patients-with-Relapsed-Refractory.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761103
https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugs-dont-make-whos-essential-list-ebola-ms-drugs-added-2023-07-26/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-application-for-biosimilar-candidate-accepted-for-review-by-usfda/articleshow/101704158.cms
https://www.reuters.com/business/healthcare-pharmaceuticals/adc-therapeutics-pauses-enrolment-mid-stage-trial-cancer-therapy-2023-07-11/
https://endpts.com/artiva-boasts-early-nk-cell-therapy-results-giving-lifeline-to-partner-affimed/
https://www.globenewswire.com/news-release/2023/05/26/2676842/0/en/Roche-to-present-new-data-in-blood-cancers-and-solid-tumours-from-its-broad-portfolio-at-ASCO-2023.html
https://endpts.com/fda-adcomm-votes-11-2-to-expand-roches-polivy-label-in-dlbcl/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-completes-clinical-studies-of-its-proposed-rituximab-biosimilar-candidate/articleshow/97163863.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.fiercepharma.com/pharma/beigene-keeps-momentum-going-brukinsa-winning-nice-recommendation-wm
https://www.thepharmaletter.com/article/fda-accepts-supplemental-biologics-license-application-for-roche-s-polivy-combination
https://www.labiotech.eu/trends-news/genentech-lymphoma-treatment/
https://www.prnewswire.com/news-releases/fda-approves-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab-for-adults-with-moderate-to-severe-rheumatoid-arthritis-301561556.html
https://www.expresspharma.in/european-commission-approves-roches-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma/
https://www.reuters.com/business/healthcare-pharmaceuticals/fresenius-agrees-two-acquisition-deals-bolster-kabi-drugs-unit-2022-03-31/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761088
https://www.prnewswire.com/news-releases/nordic-nanovector-provides-update-on-paradigme-its-phase-2b-pivotal-trial-with-betalutin-in-rr-follicular-lymphoma-301456433.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705
https://www.cancernetwork.com/view/progression-free-survival-boost-noted-with-polatuzumab-vedotin-plus-r-chp-for-previously-untreated-dlbcl
https://www.prnewswire.com/news-releases/i-mab-presents-interim-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-relapsed-and-refractory-non-hodgkin-lymphoma-at-ash-2021-301443905.html
https://www.prnewswire.com/news-releases/i-mab-to-hold-investor-call-to-present-in-depth-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-non-hodgkinss-lymphoma-301440967.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705
https://www.globenewswire.com/news-release/2021/11/12/2333443/19219/en/Positive-Recommendation-for-Use-of-TAVNEOS-avacopan-in-ANCA-Vasculitis-Adopted-by-European-Medicines-Agency-EMA-Committee-for-Medicinal-Products-for-Human-Use-CHMP.html
https://www.prnewswire.com/news-releases/i-mab-to-present-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-non-hodgkinss-lymphoma-at-ash-2021-301416284.html
https://www.news-medical.net/news/20211102/Immunocompromised-patients-using-rituximab-could-benefit-from-third-COVID-19-booster-vaccine.aspx
https://www.chugai-pharm.co.jp/english/news/detail/20210927170000_853.html